Androgen-dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and clinical implications

Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications

Volumn , Issue , 2012, Pages 307-328

  Dobi, Albert ^a   Sreenath, Taduru ^a   Srivastava, Shiv ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Androgen receptor; ERG oncogene; ERG oncoprotein; ETS transcription factors; Gene fusion; Hormonal regulation; Prostate cancer

Indexed keywords

EID: 84890118835     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6182-1_19     Document Type: Chapter

References (154)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269
3. Richter E, Srivastava S, Dobi A (2007) Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 10:114-118
4. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF et al (2008) Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 72:S12-S24
5. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8:497-511
6. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443-454
7. Knudsen BS, Vasioukhin V (2010) Mechanisms of prostate cancer initiation and progression. Adv Cancer Res 109:1-50
8. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586
9. Sreenath TL, Dobi A, Petrovics G, Srivastava S (2011) Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog 10:37
10. Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A (2012) Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol 9:131-137
11. De Marzo AM, Nelson WG, Bieberich CJ, Yegnasubramanian S (2010) Prostate cancer: new answers prompt new questions regarding cell of origin. Nat Rev Urol 7:650-652
12. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967-2000
13. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44:685-689
14. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM (2010) MYC and prostate cancer. Genes Cancer 1:617-628
15. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15:4799-4805.
16. Ryan CJ, Tindall DJ (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29:3651-3658
17. Nadiminty N, Gao AC (2012) Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol 30:287-295
18. Hollenhorst PC, McIntosh LP, Graves BJ (2011) Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80:437-471
19. Rubin MA (2012) ETS rearrangements in prostate cancer. Asian J Androl 14:393-399
20. Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H (2011) PCA3: from basic molecular science to the clinical lab. Cancer Lett 301:1-6
21. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M et al (2002) Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160:2169-2180
22. Vanaja DK, Cheville JC, Iturria SJ, Young CY (2003) Transcriptional silencing of zincfinger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63:3877-3882
23. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C et al (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24:3847-3852
24. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648
25. Rubin MA, Maher CA, Chinnaiyan AM (2011) Common gene rearrangements in prostate cancer. J Clin Oncol 29:3659-3668
26. Svensson MA, LaFargue CJ, MacDonald TY, Pflueger D, Kitabayashi N et al (2011) Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Investig 91:404-412
27. Wang Q, Li W, Liu XS, Carroll JS, Janne OA et al (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380-392
28. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K et al (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793-798
29. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68: 8516-8524
30. Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG et al (2008) Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem 54:2007-2017
31. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY et al (2008) Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 14:4719-4725
32. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH et al (2007) Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97:1690-1695
33. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA et al (2009) TMPRSS2- ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69:1400-1406
34. St John J, Powell K, Conley-LaComb MK, Chinni SR (2012) TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J Cancer Sci Ther 4:94-101
35. Mehra R, Han B, Tomlins SA, Wang L, Menon A et al (2007) Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67:7991-7995
36. Barry M, Perner S, Demichelis F, Rubin MA (2007) TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70:630-633
37. Clark J, Attard G, Jhavar S, Flohr P, Reid A et al (2008) Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27:1993-2003
38. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J et al (2008) Mapping of TMPRSS2- ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21:67-75
39. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM et al (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15:4706-4711
40. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J et al (2010) ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 75:762-767
41. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS et al (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41:524-526
42. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L et al (2011) TMPRSS2-ERG-mediated feedforward regulation of wild-type ERG in human prostate cancers. Cancer Res 71:5387-5392
43. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK et al (2009) Induced chromosomal proximity and gene fusions in prostate cancer. Science 326:1230
44. Lin C, Yang L, Tanasa B, Hutt K, Ju BG et al (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139:1069-1083
45. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R et al (2010) Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42:668-675
46. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A et al (2010) Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 16:1572-1576
47. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C et al (2011) TMPRSS2- ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71:489-497
48. Rosen P, Pfister D, Young D, Petrovics G, Chen Y et al (2012) Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American Patients With Prostate Cancer. Urology 80:749-753
49. Oikawa T, Yamada T (2003) Molecular biology of the Ets family of transcription factors. Gene 303:11-34
50. Ichikawa H, Shimizu K, Hayashi Y, Ohki M (1994) An RNA-binding protein gene, TLS/ FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54:2865-2868
51. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P et al (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337-3343
52. Sorensen PH, Chen CS, Smith FO, Arthur DC, Domer PH et al (1994) Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 93:429-437
53. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K et al (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242
54. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S et al (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66:10242-10246
55. Nelson WG, De Marzo AM, Yegnasubramanian S (2009) Epigenetic alterations in human prostate cancers. Endocrinology 150:3991-4002
56. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A et al (2010) ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 5:e10547
57. Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3:300-309.
58. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T et al (2010) FZD4 as a mediator of ERG oncogene- induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 70:6735-6745
59. Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R et al (2011) Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 39:111-119
60. Buttice G, Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen M, Stehelin D (1996) Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13:2297-2306
61. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J et al (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-188
62. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M et al (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105:2105-2110
63. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S et al (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41:619-624
64. Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S et al (2010) Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Transl Oncol 3:195-203
65. Flajollet S, Tian TV, Flourens A, Tomavo N, Villers A et al (2011) Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. Mol Cancer Res 9:914-924
66. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R et al (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271-2277
67. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL et al (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27:5348-5353
68. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON (2009) ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 106:12465-12470
69. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890
70. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I et al (2011) TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 6:e21650
71. Mochmann LH, Bock J, Ortiz-Tanchez J, Schlee C, Bohne A et al (2011) Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene 30:2044-2056
72. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S et al (2010) Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 9:55
73. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD (2009) ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell 20:2207-2217
74. Martin SK, Kyprianou N (2011) Gene fusionsfind an ERG-way to tumor inflammation. Cancer Biol Ther 11:418-420
75. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N et al (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-1333
76. Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y et al (2011) ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 11:410-417
77. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q et al (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664-678
78. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010) Identification of a cell of origin for human prostate cancer. Science 329:568-571
79. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22
80. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K et al (2011) The genomic complexity of primary human prostate cancer. Nature 470:214-220
81. Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J et al (2010) ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12:1031-1040
82. Chng KR, Chang CW, Tan SK, Yang C, Hong SZ et al (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 31:2810-2823
83. Masuda K, Werner T, Maheshwari S, Frisch M, Oh S et al (2005) Androgen receptor binding sites identified by a GREF-GATA model. J Mol Biol 353:763-771
84. Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM et al (2009) Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein Cancer Res 69:8102-8110
85. Wei GH, Badis G, Berger MF, Kivioja T, Palin K et al (2010) Genome-wide analysis of ETSfamily DNA-binding in vitro and in vivo. EMBO J 29:2147-2160
86. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ (2011) Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 25:2147-2157
87. Shaikhibrahim Z, Wernert N (2012) ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review). Int J Oncol 40:1748-1754
88. Dayyani F, Gallick GE, Logothetis CJ, Corn PG (2011) Novel therapies for metastatic castrate- resistant prostate cancer. J Natl Cancer Inst 103:1665-1675
89. Azzouni F, Godoy A, Li Y, Mohler J (2012) The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012:530121
90. Kohli M, Qin R, Jimenez R, Dehm SM (2012) Biomarker-based targeting of the androgen- androgen receptor axis in advanced prostate cancer. Adv Urol 2012:781459
91. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD et al (2006) Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25:3905-3913
92. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D (2007) Expression of androgen receptor is negatively regulated by p53. Neoplasia 9:1152-1159
93. Guseva NV, Rokhlin OW, Glover RA, Cohen MB (2012) P53 and the proteasome regulate androgen receptor activity. Cancer Biol Ther 13:553-558
94. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454
95. Romics I, BanfiG, Szekely E, Krenacs T, Szende B (2008) Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res 14:307-311
96. Qiu YQ, Leuschner I, Braun PM (2008) Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. Asian J Androl 10:855-863
97. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S et al (2008) Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 61:448-454
98. Szabo J, Bartok K, Krenacs T, Szepesvary Z, Szende B (2009) GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Anticancer Res 29:681-684
99. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P et al (2010) Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 105:462-467
100. Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R et al (2000) Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 163:972-979
101. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M et al (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21:8749-8758
102. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM et al (2004) Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145:3913-3924
103. Dehm SM, Tindall DJ (2006) Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99:333-344
104. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808
105. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG et al (2008) A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem 283:28988-28995
106. Wang Q, Li W, Zhang Y, Yuan X, Xu K et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256
107. Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J et al (2010) Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res 70:1286-1295
108. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393-406
109. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J (2006) TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgendependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66:10658-10663
110. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L et al (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39:41-51
111. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S et al (2008) Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clinical Cancer Res 14:758-763
112. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A et al (2009) Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 27:2022-2029
113. Foley R, Hollywood D, Lawler M (2004) Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 11:477-488
114. Dobi A, Furusato B, Shaheduzzaman S, Chen Y, Vahey M et al (2010) ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoters. Open Cancer J 3:101-108
115. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM et al (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66:8337-8341
116. Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347-8351
117. Demichelis F, Fall K, Perner S, Andren O, Schmidt F et al (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596-4599
118. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S et al (2007) Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60:1238-1243
119. Rowley JD (2009) Chromosomes in leukemia and beyond: from irrelevant to central players. Annu Rev Genomics Hum Genet 10:1-18
120. Netto GJ, Epstein JI (2010) Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 42:384-394
121. Netto GJ (2011) Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med 135:610-621
122. Attard G, de Bono JS, Clark J, Cooper CS (2010) Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. Clin Cancer Res 16:1340, author reply 40
123. Yaskiv O, Zhang X, Simmerman K, Daly T, He H et al (2011) The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 35:1062-1068
124. Leman ES, Getzenberg RH (2009) Biomarkers for prostate cancer. J Cell Biochem 108:3-9
125. Gao X, Li LY, Zhou FJ, Xie KJ, Shao CK et al (2012) ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin Cancer Res 18:4163-4172
126. Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429-439
127. Winnes M, Lissbrant E, Damber JE, Stenman G (2007) Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 17:1033-1036
128. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14:3395-3400
129. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17:5878-5888
130. Tan S-H, Ruiz C, Braun M, Scheble V, Zellweger T et al (2012) TMPRSS2-ERG translocation during prostate cancer progression. J Urol 187(Suppl):e129
131. Boormans JL, Porkka K, Visakorpi T, Trapman J (2011) Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer. Eur Urol 60:183-184
132. Furusato B, Tan SH, Young D, Dobi A, Sun C et al (2010) ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13:228-237
133. Squire JA (2009) TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 41:509-510
134. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J et al (2008) Afirst-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68: 645-649
135. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3:94ra72
136. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA (2009) Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. Prostate 69:1624-1634
137. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA et al (2010) Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 70:10-16
138. Lee GL, Dobi A, Srivastava S (2011) Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol 8:123-124
139. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R et al (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12:590-598
140. Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K et al (2011) ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 459:441-447
141. McLeod DG, Dobi A (2011) Re: antibody-based detection of ERG rearrangement-positive prostate cancer. Eur Urol 60:1123
142. Lee G, Russell D, Parker P, Sesterhenn IA, Cullen J et al (2011) Improved detection of prostate cancer by the combined application of ERG and AMACR immunohistochemical stainings in prostate biopsy specimens. Urology 78:S328-S329
143. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP (2012) Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 136: 935-946
144. He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S et al (2011) The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol 35:608-614
145. Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V et al (2010) Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer 1:197-208
146. Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A et al (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35:432-441
147. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS et al (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15:750-756
148. Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Uren A (2011) YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 6:e19343
149. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F et al (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589
150. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301
151. Leung M, Rosen D, Fields S, Cesano A, Budman DR (2011) Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 17:854-862
152. Sandhu SK, Yap TA, de Bono JS (2011) The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets 12:2034-2044
153. Mostaghel EA, Montgomery B, Nelson PS (2009) Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 27:251-257
154. Priolo C, Oh WK, Loda M (2009) Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs 12:165-168